In Q2, Astra reported strong sales growth momentum, (again) driven by a strong showing in oncology, diabetes drug Farxiga and COVID-19 vaccine sales. Although there were some issues in R&I and CVRM. More importantly, at cost vaccine sales and mandatory VBP discounts in China weighed on profitability. While the profitability strain can sustain in H2 as well, one should find confidence from the robust potential of core pharma offerings and the addition of high-growth and excellent-margin Alexion, ....
02 Aug 2021
Healthy sales growth blotted by near-term margin pressure
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy sales growth blotted by near-term margin pressure
AstraZeneca PLC (AZN:LON) | 10,183 -10794 (-1.0%) | Mkt Cap: 157,857m
- Published:
02 Aug 2021 -
Author:
Amandeep Goyal -
Pages:
5
In Q2, Astra reported strong sales growth momentum, (again) driven by a strong showing in oncology, diabetes drug Farxiga and COVID-19 vaccine sales. Although there were some issues in R&I and CVRM. More importantly, at cost vaccine sales and mandatory VBP discounts in China weighed on profitability. While the profitability strain can sustain in H2 as well, one should find confidence from the robust potential of core pharma offerings and the addition of high-growth and excellent-margin Alexion, ....